CTXR - Citius Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cranford,
United States
Type: Equity
CTXR price evolution
CTXR
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $17.95 | $12.6 | $20.38 | $26.52 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $28.01 | $21.57 | $28.21 | $34.37 |
| Long term investments | ||||
| Property, plant & equipment | $0.3 | $0.35 | $0.4 | $0.46 |
| Goodwill & intangible assets | $9.35 | $9.35 | $9.35 | $9.35 |
| Total noncurrent assets | $69.08 | $69.14 | $69.19 | $69.24 |
| Total investments | ||||
| Total assets | $97.09 | $90.71 | $97.4 | $103.61 |
| Current liabilities | ||||
| Accounts payable | $1.66 | $2.67 | $2.65 | $2.93 |
| Deferred revenue | ||||
| Short long term debt | $0.24 | $0.23 | $0.22 | $0.22 |
| Total current liabilities | $4.15 | $4.17 | $5.58 | $5.78 |
| Long term debt | $0.08 | $0.15 | $0.2 | $0.26 |
| Total noncurrent liabilities | $6.65 | $6.57 | $6.49 | $6.4 |
| Total debt | $0.32 | $0.37 | $0.43 | $0.48 |
| Total liabilities | $10.81 | $10.74 | $12.07 | $12.18 |
| Shareholders' equity | ||||
| Retained earnings | -$190.58 | -$180.01 | -$171.46 | -$162.23 |
| Other shareholder equity | ||||
| Total shareholder equity | $85.68 | $79.37 | $84.73 | $90.83 |
| (in millions $) | 31 Dec 2023 | 30 Oct 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $26.52 | $41.75 | $70.11 | $13.92 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $34.37 | $44.56 | $72.81 | $13.98 |
| Long term investments | ||||
| Property, plant & equipment | $0.46 | $0.65 | $0.83 | $0.99 |
| Goodwill & intangible assets | $9.35 | $9.35 | $9.35 | $9.35 |
| Total noncurrent assets | $69.24 | $69.44 | $69.61 | $29.79 |
| Total investments | ||||
| Total assets | $103.61 | $114 | $142.43 | $43.77 |
| Current liabilities | ||||
| Accounts payable | $2.93 | $1.17 | $1.28 | $1.86 |
| Deferred revenue | ||||
| Short long term debt | $0.22 | $0.2 | $0.18 | $0.33 |
| Total current liabilities | $5.78 | $4.53 | $3.98 | $4.1 |
| Long term debt | $0.26 | $0.48 | $0.68 | $1.02 |
| Total noncurrent liabilities | $6.4 | $6.04 | $5.66 | $6.01 |
| Total debt | $0.48 | $0.68 | $0.86 | $1.35 |
| Total liabilities | $12.18 | $11.17 | $9.65 | $10.1 |
| Shareholders' equity | ||||
| Retained earnings | -$162.23 | -$129.69 | -$96.05 | -$70.59 |
| Other shareholder equity | ||||
| Total shareholder equity | $90.83 | $102.83 | $132.18 | $33.67 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $2.76 | $3.61 | $2.62 | $2.88 |
| Selling, general & administrative | $4.81 | $4.29 | $3.66 | $4.17 |
| Total operating expenses | $10.63 | $10.97 | $9.34 | $10.12 |
| Operating income | -$10.63 | -$10.97 | -$9.34 | -$10.12 |
| Income from continuing operations | ||||
| EBIT | -$10.43 | -$8.4 | -$9.09 | -$9.8 |
| Income tax expense | $0.14 | $0.14 | $0.14 | $0.14 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$10.57 | -$8.54 | -$9.23 | -$9.94 |
| Income (for common shares) | -$10.89 | -$8.54 | -$9.23 | -$11.1 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $14.82 | $17.66 | $12.24 | $8.81 |
| Selling, general & administrative | $15.3 | $11.75 | $9.84 | $8.09 |
| Total operating expenses | $36.73 | $33.32 | $23.53 | $17.71 |
| Operating income | -$36.73 | -$33.32 | -$23.53 | -$17.71 |
| Income from continuing operations | ||||
| EBIT | -$31.97 | -$33.06 | -$23.04 | -$17.53 |
| Income tax expense | $0.58 | $0.58 | ||
| Interest expense | $0.01 | $0.02 | ||
| Net income | ||||
| Net income | -$32.54 | -$33.64 | -$23.05 | -$17.55 |
| Income (for common shares) | -$33.69 | -$33.64 | -$24.51 | -$17.55 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$10.57 | -$8.54 | -$9.23 | -$9.94 |
| Operating activities | ||||
| Depreciation | $0.05 | $0.05 | $0.05 | $0.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.17 | $3.18 | $3.13 | $3.08 |
| Total cash flows from operations | -$8.37 | -$7.79 | -$6.14 | -$6.8 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $13.72 | -$0 | ||
| Net borrowings | ||||
| Total cash flows from financing | $13.72 | -$0 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $5.35 | -$7.79 | -$6.14 | -$6.8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$32.54 | -$33.64 | -$23.05 | -$17.55 |
| Operating activities | ||||
| Depreciation | $0.19 | $0.18 | $0.16 | $0.15 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.72 | $4.28 | $1.52 | $1.33 |
| Total cash flows from operations | -$29.06 | -$28.36 | -$24.25 | -$16.93 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0 | ||
| Investments | ||||
| Total cash flows from investing | -$40.01 | -$0 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $13.83 | $120.64 | $22.73 | |
| Net borrowings | -$0.17 | $0.16 | ||
| Total cash flows from financing | $13.83 | $120.47 | $22.9 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$15.23 | -$28.36 | $56.21 | $5.97 |
News
Fundamentals
| Market cap | $469.89M |
|---|---|
| Enterprise value | $452.26M |
| Shares outstanding | 180.73M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$37.51M |
| EBIT | -$37.72M |
| Net Income | -$38.29M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -12.27 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -12.06 |
| EV/EBIT | -11.99 |
| P/S ratio | N/A |
| P/B ratio | 5.48 |
| Book/Share | 0.47 |
| Cash/Share | 0.10 |
| EPS | -$0.21 |
|---|---|
| ROA | -39.39% |
| ROE | -44.97% |
| Debt/Equity | 0.13 |
|---|---|
| Net debt/EBITDA | 0.19 |
| Current ratio | 6.75 |
| Quick ratio | 6.75 |